LXRA has a 100-fold higher binding affinity than LXRB for the corepressors NCOR1 and NCOR2 [12] and deregulation of these corepressors allows prostate and bladder cancer cells to evade cancer suppressive signals of Vitamin D (through repression of Vitamin D Receptor (VDR)) and omega-3 fatty acids (through repression of peroxisome proliferator-activated receptors (PPARs)) by impairing sensitivity to ligand [10,11,13]. The gene discussed is VDR; the disease is urinary bladder cancer.